What are the NCCN and ESMO treatment recommendations for non-Hodgkin lymphoma (NHL)?

Updated: Jun 12, 2019
  • Author: Priyank P Patel, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Answer

The NCCN and ESMO offer similar treatment recommendations, as follows [1, 13] :

  • Involved-site radiation therapy (ISRT), 24-30 Gy, is the preferred treatment option for stage I or II

  • If significant toxicity is expected from radiotherapy, initial observation may be more appropriate

  • Other first-line treatment options include rituximab, alone or in combination with other agents, and radioimmunotherapy

  • Combination treatment with involved-field radiation therapy (IFRT) and chemotherapy (see below) and/or radioimmunotherapy is recommended for more advanced stages

  • In asymptomatic patients with advanced-stage, low tumor burden disease, initiate treatment when the patients become symptomatic, as there is no survival advantage with immediate treatment versus a watch-and-wait approach


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!